Kerdan Group

We are a boutique strategy consulting rm based out of Kendall Square, the biotech center of Cambridge, MA. We work with biopharma development and disease area teams, bringing experience, perspective, objectivity, and fresh ideas to the major strategic decisions that they face: • Asset Development Strategy • Disease Area Strategy and Proof of Concept Denition • Insight Book Creation • Process and Capability Design Since Kerdan was founded by Thom Doyle and Matt Hall in 2001, we’ve worked with 7 of the top 10 global biopharma companies. In metabolic, cardiovascular, ophthalmologic, oncologic, CNS, and inammatory disease areas, we have helped our clients dream up great ideas about developing better medicines. Underlying our work is a mindset and approach we call inspire-prototype-adapt. Given the complexities and uncertainties in drug development, we believe this mindset is necessary to overcome adversity and maximize serendipity. Our clients—leaders trying to deliver real benets to patients— don’t believe that the system is unchangeable. Their success rests on their ability to look forward. They require a creative process to generate new, better alternatives. Our approach creates better options because it rests on open-minded collaboration, skilled observation and inquiry, and prototyping to continually advance our clients’ and our own thinking. The result is a proactive approach to create the future out of what is now whitespace.